IκK/IκB

BX-795 is a potent PDK1 inhibitor that blocks PDK1/Akt signaling in tumor cells and inhibits the anchorage-dependent growth of a variety of tumor cell lines in culture or induced apoptosis.

Bardoxolone methyl, previously known as RTA 402, is the lead molecule in Reata's portfolio of Antioxidant Inflammation Modulators (AIMs).

Bay 65-1942 is an ATP-competitive inhibitor that selectively targets IKKβ kinase activity.

IKK-2 inhibitor VIII is a potent and selective IKK-2 inhibitor with IC50 of 8.5 nM.

IKK-3 Inhibitor is a potent, selective, inhibitor of IKK-epsilon kinase with IC50 of 40 nM; inactive at IKK-alpha and IKK-beta.

MRT67307 is a potent and dual IKKε and TBK1 inhibitor with IC50 of 160 and 19 nM, respectively.

PHA 408 is a potent, highly selective and ATP-competitive IKB kinase-2 (IKK-2) inhibitor (IC50: 40 nM), which binds IKK-2 tightly with a relatively slow off rate; highly recommended tool to investigate the mechanisms by which IKK-2 regulates NF-KB signaling.

BI605906 is a novel inhibitors of the IKK beta.

Wedelolactone, a compound originally extracted from Eclipta alba, has been shown to inhibit caspase-11, which is a key regulator of proinflammatory cytokine IL-1β maturation and pathological apoptosis.

AZD3264 is a novel IKK2 inhibitor.

INH14 is a cell permeable inhibitor of IKKα/IKKβ, with IC50s of 8.97 and 3.59 μM, respectively.

IMD-0560 is a novel IκB kinase β inhibitor.

IKK-IN-1 is an inhibitor of IKK extracted from patent WO2002024679A1, compound example 18-13.